Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Research Field Cell & gene therapy, Neuroscience

Changing the Leopard’s Spots

A new transdifferentiation protocol has yielded 60 percent dopaminergic neurons from human fibroblasts after 10 days. The conversion rate achieved by the researchers from the Jacobs School of Medicine and Biomedical Sciences at the University of Buffalo, USA, is a substantial improvement on the five percent in 15–20 days attained via other methods.

Previous studies had found that attenuating the p53 pathway made it much easier to generate induced pluripotent stem cells. “This inspired us to find out whether knocking down p53 would have an effect on transdifferentiation,” says Jian Feng, lead author of the study. “And to our surprise, it did.”

Enjoy our FREE content!

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!

Login if you already created an account

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
Register

Or Login as a Guest or via Social Media

Related Solutions

Research Field

Dental Curing Lights: Clinical Reality

| Contributed by Ocean Optics

Research Field

Measuring DNA Absorbance with the STS-UV

| Contributed by Ocean Optics

Newsletter

Send me the latest from The Translational Scientist.

Sign up now

Related Articles

Research Field

The Power To Change Lives

| Stephanie Sutton

Research Field

Bearfaced Research

| Roisin McGuigan

Research Field

Not Immune to Damage

| Ruth Steer

Most Popular

Register here

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register